Study Information

Home / Study Information

CREDO 3


There is no cost to you for this study (study drug, the labs, the visits), and you will be reimbursed $30.00 per completed study visit for transport costs. This study is primarily to evaluate the efficacy and safety of the study drug Olokizumab (OKZ) relative to placebo in subjects with moderately to severely active RA inadequately controlled by TNF-alpha inhibitor therapy. This drug will be administered subcutaneously (injected under the skin) once every 2 weeks or once every 4 weeks. The study lasts about 48 weeks: 4 weeks for screening, a 24-week treatment period, and then a 20-week safety follow-up.

Indication: RA - Rheumatoid Arthritis
Protocol number: CL04041025
Phase: 3
Possible Stipend: $ 0